On the other hand, marijuana-derived CBD and anything else derived from a cannabis plant was still classified by the DEA as a Schedule I drug (defined as a drug with "no currently accepted medical use and a high potential for abuse") until October 2018. In 2016, the DEA stated that all extracts containing more than one cannabinoid would remain classified as Schedule I. However, the approval of Epidiolex had an influence in changing this, and prescription CBD drugs with a THC content of below 0.1% have now been reclassified as Schedule 5, the lowest rating.
So am I to assume, due to no response/deleted comment that my simple question was too difficult to answer? With all the technical & correct information you have on you GREAT website, can someone (?) not simply correct or acknowledge the FACT the your NOT using nano-particle size product? I am truly interesting (for my wife) in CBD, have done my research, and I love working with numbers which is why if found this discrepancy. Comments welcome, but avoidance is disturbing.